Elamin, Ayssar, Klunkelfuß, Saskia, Kämpfer, Susanne, Oehlmann, Wulf, Stehr, Matthias, Smith, Christopher, Simpson, Guy, Morgan, Richard ORCID: https://orcid.org/0000-0002-8721-4479, Pandha, Hardev and Singh, Mahavir (2020) A specific blood signature reveals higher levels of S100A12: a potential bladder cancer diagnostic biomarker along with urinary Engrailed-2 protein detection. Frontiers in Oncology, 9. p. 1484.

Preview

PDF EN2 lat flow test Lionex 2020.pdf - Published Version Available under License Creative Commons Attribution. Download (3MB) | Preview

Abstract

Urothelial carcinoma of the urinary bladder (UCB) or Bladder cancer remains a major health problem with high morbidity and mortality rates, especially in the western world. UCB is also associated with the highest cost per patient. In recent years numerous markers have been evaluated for suitability in UCB detection and surveillance. However, to date none of these markers can replace or even reduce the use of routine tools (cytology and cystoscopy). Our current study described the UCB's extensive expression profile and highlighted the variations with normal bladder tissue. Our data revealed that JUP, PTGDR, KLRF1, MT-TC and RNU6-135P are associated with prognosis in patients with UCB. The microarray expression data identified also S100A12, S100A8 and NAMPT as potential UCB biomarkers. Pathway analysis revealed that natural killer cell mediated cytotoxicity is the most involved pathway. Our analysis showed that S100A12 protein may be useful as a biomarker for early UCB detection. Plasma S100A12 has been observed in patients with UCB with an overall sensitivity of 90.5% and a specificity of 75%. S100A12 is highly expressed preferably in high-grade and high-stage UCB. Furthermore, using a panel of more than hundred urine samples, a prototype lateral flow test for the transcription factor Engrailed-2 (EN2) also showed reasonable sensitivity (85%) and specificity (71%). Such findings provide confidence to further improve and refine the EN2 rapid test for use in clinical practice. In conclusion, S100A12 and EN2 have shown potential value as biomarker candidates for UCB patients. These results can speed up the discovery of biomarkers, improving diagnostic accuracy and may help the management of UCB.

Item Type:	Article
Identifier:	10.3389/fonc.2019.01484
Additional Information:	This is the published version of an article [Elamin AA, Klunkelfuß S, Kämpfer S, Oehlmann W, Stehr M, Smith C, Simpson GR, Morgan R, Pandha Hand Singh M (2020) A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein Detection. Front. Oncol. 9: 1484. doi: 10.3389/fonc.2019.01484] which first appeared in Frontiers Media on 09/01/2020. The datasets generated and analyzed in this study areavailable under the following link in the Gene ExpressionOmnibus (GEO): https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138118. The Supplementary Material for this article can be foundonline at: https://www.frontiersin.org/articles/10.3389/fonc.2019.01484/full#supplementary-material
Keywords:	bladder, cancer, microarray, S100A12, plasma, EN2, lateral flow, urine
Subjects:	Natural sciences > Cell and molecular biology
Related URLs:	Publisher Publisher
Depositing User:	Richard Morgan
Date Deposited:	08 Jul 2020 15:07
Last Modified:	04 Nov 2024 11:48
URI:	https://repository.uwl.ac.uk/id/eprint/7167

Downloads

Actions (login required)

View Item